Using tumor samples to predict chemotherapy response in bile duct cancer

This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.

This trial tests a combination of low-dose chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (PD-1/PD-L1 antibody) for people with intrahepatic cholangiocarcinoma, a type of bile duct cancer inside the liver. The goal is to see if this combination can help shrink tumors or slow their growth.

This trial tests whether growing your tumor cells in the lab to see which drugs kill them can help choose a more effective treatment for your advanced bile duct cancer. If you join, your treatment may be personalized based on how your tumor responds to different drugs.

This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.

This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.

This study tests a treatment for intrahepatic cholangiocarcinoma (a type of liver cancer) that can be surgically removed. It combines the usual chemotherapy drugs (cisplatin and gemcitabine) with the immunotherapy drug durvalumab, and compares it to the same regimen plus a targeted therapy called futibatinib, which works on specific genetic changes in the tumor. The goal is to see if adding the targeted therapy helps shrink the tumor before surgery and improves the outcome.